Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC lifted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 23.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 171,575 shares of the biotechnology company’s stock after purchasing an additional 32,670 shares during the quarter. WCM Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $9,891,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $25,000. First Horizon Corp acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $32,000. WPG Advisers LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 431 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 177.1% during the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $54,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Down 3.6%

NASDAQ:ARWR opened at $71.65 on Tuesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The company’s fifty day moving average price is $77.50 and its 200-day moving average price is $69.51. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.30 and a 1-year high of $87.83. The firm has a market capitalization of $10.09 billion, a P/E ratio of -33.33 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same period in the previous year, the firm posted $2.75 earnings per share. The firm’s quarterly revenue was down 86.4% on a year-over-year basis. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.07 EPS for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 26,065 shares of company stock worth $1,912,662. Insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ARWR. Chardan Capital restated a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 30th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Sanford C. Bernstein raised their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, JPMorgan Chase & Co. lifted their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $88.75.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.